Prestige Consumer Healthcare (NYSE:PBH) Upgraded at Zacks Research

Zacks Research upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a strong sell rating to a hold rating in a report published on Monday morning,Zacks.com reports.

Several other equities research analysts also recently issued reports on PBH. Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective for the company in a research report on Wednesday, September 24th. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Oppenheimer dropped their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Jefferies Financial Group reduced their price target on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.33.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $60.46 on Monday. Prestige Consumer Healthcare has a one year low of $59.18 and a one year high of $90.04. The company has a market cap of $2.91 billion, a P/E ratio of 14.19, a P/E/G ratio of 1.93 and a beta of 0.41. The firm’s fifty day moving average price is $62.58 and its two-hundred day moving average price is $72.78. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The company had revenue of $274.11 million during the quarter, compared to analysts’ expectations of $257.14 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. Prestige Consumer Healthcare’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Equities analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds have recently added to or reduced their stakes in the stock. UMB Bank n.a. raised its holdings in Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock valued at $26,000 after acquiring an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Maseco LLP bought a new position in shares of Prestige Consumer Healthcare in the second quarter worth $27,000. First Horizon Corp acquired a new position in Prestige Consumer Healthcare in the third quarter valued at about $32,000. Finally, Geneos Wealth Management Inc. raised its stake in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.